Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1214–1218. doi: 10.1128/aac.40.5.1214

Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

J P Gangneux 1, A Sulahian 1, Y J Garin 1, R Farinotti 1, F Derouin 1
PMCID: PMC163294  PMID: 8723469

Abstract

The tolerance and efficacy of amphotericin B (AmB) deoxycholate (Fungizone) were compared with those of liposomal AmB (AmBisome) in a murine model of visceral leishmaniasis induced by Leishmania infantum. Control groups consisted of untreated mice and mice treated with a pentavalent antimonial (Glucantime). BALB/c mice were infected intravenously on day 0 with 10(7) promastigotes of L. infantum and then treated from day 7 to 17 (early treatment group) or from day 60 to 70 (delayed treatment group). The pentavalent antimonial was administered daily by intraperitoneal injection, whereas AmB formulations were administered intravenously on alternate days. On days 20, 60, and 120 (early treatment group) and on days 72 and 125 (delayed treatment group), parasite burdens in the liver, spleen, and lungs were determined by subculturings using a microtitration method. A dose range study showed that administration of AmBisome at the well-tolerated doses of 5 or 50 mg/kg of body weight completely eradicated the parasites from the tissues. At 0.8 mg/kg, AmBisome proved more efficacious than AmB deoxycholate administered at the same dose. We also compared the levels of AmB deoxycholate and AmBisome in plasma and tissue. Mice treated with AmBisome had levels of AmB in tissue much higher than did AmB deoxycholate-treated mice with persistent detectable levels 14 weeks after treatment. These results seem to account for the remarkable efficacy of the liposomal formulation of AmB in the treatment of visceral leishmaniasis due to L. infantum.

Full Text

The Full Text of this article is available as a PDF (207.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 1994;14 (Suppl 5):S3–S7. [PubMed] [Google Scholar]
  2. Alvar J., Gutiérrez-Solar B., Molina R., López-Velez R., Garcia-Camacho A., Martinez P., Laguna F., Cercenado E., Galmes A. Prevalence of Leishmania infection among AIDS patients. Lancet. 1992 Jun 6;339(8806):1427–1427. doi: 10.1016/0140-6736(92)91255-7. [DOI] [PubMed] [Google Scholar]
  3. Berman J. D., Ksionski G., Chapman W. L., Waits V. B., Hanson W. L. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother. 1992 Sep;36(9):1978–1980. doi: 10.1128/aac.36.9.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buffet P. A., Sulahian A., Garin Y. J., Nassar N., Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother. 1995 Sep;39(9):2167–2168. doi: 10.1128/aac.39.9.2167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Collins M., Carter K. C., Baillie A. J. Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann Trop Med Parasitol. 1992 Feb;86(1):35–40. doi: 10.1080/00034983.1992.11812628. [DOI] [PubMed] [Google Scholar]
  6. Davidson R. N., Croft S. L., Scott A., Maini M., Moody A. H., Bryceson A. D. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet. 1991 May 4;337(8749):1061–1062. doi: 10.1016/0140-6736(91)91708-3. [DOI] [PubMed] [Google Scholar]
  7. Davidson R. N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G. B., Pempinello R., Scott S., Raimondi F., Cascio A. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994 Feb;87(2):75–81. [PubMed] [Google Scholar]
  8. Davidson R. N., Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis. 1994 Sep;19(3):560–560. doi: 10.1093/clinids/19.3.560. [DOI] [PubMed] [Google Scholar]
  9. Dereure J., Reynes J., Pratlong F., Lamaury I., Rioux J. A., Janbon F., Dedet J. P. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull World Health Organ. 1995;73(2):245–246. [PMC free article] [PubMed] [Google Scholar]
  10. Dietze R., Fagundes S. M., Brito E. F., Milan E. P., Feitosa T. F., Suassuna F. A., Fonschiffrey G., Ksionski G., Dember J. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg. 1995 May-Jun;89(3):309–311. doi: 10.1016/0035-9203(95)90557-x. [DOI] [PubMed] [Google Scholar]
  11. Gradoni L., Bryceson A., Desjeux P. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ. 1995;73(2):191–197. [PMC free article] [PubMed] [Google Scholar]
  12. Gradoni L., Davidson R. N., Orsini S., Betto P., Giambenedetti M. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target. 1993;1(4):311–316. doi: 10.3109/10611869308996089. [DOI] [PubMed] [Google Scholar]
  13. Janknegt R., de Marie S., Bakker-Woudenberg I. A., Crommelin D. J. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992 Oct;23(4):279–291. doi: 10.2165/00003088-199223040-00004. [DOI] [PubMed] [Google Scholar]
  14. Khoo S. H., Bond J., Denning D. W. Administering amphotericin B--a practical approach. J Antimicrob Chemother. 1994 Feb;33(2):203–213. doi: 10.1093/jac/33.2.203. [DOI] [PubMed] [Google Scholar]
  15. Lazanas M. C., Tsekes G. A., Papandreou S., Harhalakis N., Scandali A., Nikiforakis E., Saroglou G. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS. 1993 Jul;7(7):1018–1019. doi: 10.1097/00002030-199307000-00020. [DOI] [PubMed] [Google Scholar]
  16. Lopez Dupla M., Gil Aguado A., Lavilla Uriol P., Pintado Garcia V., Valencia Ortega E., Martinez Martinez P., Garcia-Puig J. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. J Antimicrob Chemother. 1993 Oct;32(4):657–659. doi: 10.1093/jac/32.4.657. [DOI] [PubMed] [Google Scholar]
  17. Mishra M., Biswas U. K., Jha A. M., Khan A. B. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994 Dec 10;344(8937):1599–1600. doi: 10.1016/s0140-6736(94)90406-5. [DOI] [PubMed] [Google Scholar]
  18. Montalban C., Calleja J. L., Erice A., Laguna F., Clotet B., Podzamczer D., Cobo J., Mallolas J., Yebra M., Gallego A. Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect. 1990 Nov;21(3):261–270. doi: 10.1016/0163-4453(90)93933-j. [DOI] [PubMed] [Google Scholar]
  19. Montalban C., Sevilla F., Moreno A., Nash R., Celma M. L., Muñoz R. F. Visceral leishmaniasis as an opportunistic infection in the acquired immunodeficiency syndrome. J Infect. 1987 Nov;15(3):247–250. doi: 10.1016/s0163-4453(87)92728-9. [DOI] [PubMed] [Google Scholar]
  20. New R. R., Chance M. L., Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother. 1981 Nov;8(5):371–381. doi: 10.1093/jac/8.5.371. [DOI] [PubMed] [Google Scholar]
  21. Panosian C. B., Barza M., Szoka F., Wyler D. J. Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1984 May;25(5):655–656. doi: 10.1128/aac.25.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rosenthal E., Marty P., Poizot-Martin I., Reynes J., Pratlong F., Lafeuillade A., Jaubert D., Boulat O., Dereure J., Gambarelli F. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg. 1995 Mar-Apr;89(2):159–162. doi: 10.1016/0035-9203(95)90476-x. [DOI] [PubMed] [Google Scholar]
  23. Seaman J., Boer C., Wilkinson R., de Jong J., de Wilde E., Sondorp E., Davidson R. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis. 1995 Jul;21(1):188–193. doi: 10.1093/clinids/21.1.188. [DOI] [PubMed] [Google Scholar]
  24. Thakur C. P., Sinha G. P., Barat D., Singh R. K. Are incremental doses of amphotericin B required for the treatment of visceral leishmaniasis? Ann Trop Med Parasitol. 1994 Aug;88(4):365–370. doi: 10.1080/00034983.1994.11812878. [DOI] [PubMed] [Google Scholar]
  25. Tollemar J., Andersson S., Ringdén O., Tydén G. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses. 1992 Sep-Oct;35(9-10):215–220. doi: 10.1111/j.1439-0507.1992.tb00850.x. [DOI] [PubMed] [Google Scholar]
  26. Torre-Cisneros J., Villanueva J. L., Kindelan J. M., Jurado R., Sanchez-Guijo P. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis. 1993 Oct;17(4):625–627. doi: 10.1093/clinids/17.4.625. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES